FOXC2 is a novel prognostic factor in human esophageal squamous cell carcinoma

Naohiro Nishida, Koshi Mimori, Takehiko Yokobori, Tomoya Sudo, Fumiaki Tanaka, Kohei Shibata, Hideshi Ishii, Yuichiro Doki, Masaki Mori

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Background: FOXC2 has been implicated in cancer progression through its induction of epithelial-to-mesenchymal transition. We analyzed the clinical significance of FOXC2 in esophageal cancer cases, in which early distant metastasis or invasion to nearby organs is an obstacle to treatment. Methods: Quantitative reverse transcriptase-polymerase chain reaction was used to evaluate FOXC2 mRNA expression in 70 esophageal cancer cases to determine the clinicopathologic significance of FOXC2 expression. Furthermore, we examined associations between FOXC2 expression and matrix metalloproteinases 2 (MMP2) and matrix metalloproteinases 9 (MMP9). We also performed in vitro invasion and migration assays for FOXC2-suppressed esophageal cancer cells. Results: In clinicopathologic analysis, the high-FOXC2 expression group showed a higher incidence of advanced tumor stage, lymph node metastasis, and lymphatic invasion than the low-FOXC2 expression group (P < 0.05). In particular, tumor stage exhibited the most remarkable difference (P < 0.0001). Expression of MMP2 and MMP9 was far higher in the high-FOXC2 expression group. Furthermore, the high-FOXC2 expression group had a significantly poorer prognosis than did the low expression group (P = 0.006). Multivariate analysis indicated that high FOXC2 expression was an independent prognostic factor for survival. Suppression of FOXC2 expression altered the invasive and the migratory ability of esophageal cancer cells in vitro. Conclusions: Our findings suggest that FOXC2 could be an important prognostic indicator for esophageal cancer patients. FOXC2 is directly involved in cancer progression and is associated with poor prognosis in esophageal cancer cases.

Original languageEnglish
Pages (from-to)535-542
Number of pages8
JournalAnnals of Surgical Oncology
Volume18
Issue number2
DOIs
Publication statusPublished - Feb 1 2011

Fingerprint

Esophageal Neoplasms
Matrix Metalloproteinase 2
Matrix Metalloproteinase 9
Neoplasms
Lymphatic Metastasis
Epithelial-Mesenchymal Transition
Reverse Transcriptase Polymerase Chain Reaction
Esophageal Squamous Cell Carcinoma
Multivariate Analysis
Lymph Nodes
Neoplasm Metastasis
Messenger RNA
Survival
Incidence

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

FOXC2 is a novel prognostic factor in human esophageal squamous cell carcinoma. / Nishida, Naohiro; Mimori, Koshi; Yokobori, Takehiko; Sudo, Tomoya; Tanaka, Fumiaki; Shibata, Kohei; Ishii, Hideshi; Doki, Yuichiro; Mori, Masaki.

In: Annals of Surgical Oncology, Vol. 18, No. 2, 01.02.2011, p. 535-542.

Research output: Contribution to journalArticle

Nishida, N, Mimori, K, Yokobori, T, Sudo, T, Tanaka, F, Shibata, K, Ishii, H, Doki, Y & Mori, M 2011, 'FOXC2 is a novel prognostic factor in human esophageal squamous cell carcinoma', Annals of Surgical Oncology, vol. 18, no. 2, pp. 535-542. https://doi.org/10.1245/s10434-010-1274-y
Nishida, Naohiro ; Mimori, Koshi ; Yokobori, Takehiko ; Sudo, Tomoya ; Tanaka, Fumiaki ; Shibata, Kohei ; Ishii, Hideshi ; Doki, Yuichiro ; Mori, Masaki. / FOXC2 is a novel prognostic factor in human esophageal squamous cell carcinoma. In: Annals of Surgical Oncology. 2011 ; Vol. 18, No. 2. pp. 535-542.
@article{f6a0ced42aa94687b30259a9f19fc730,
title = "FOXC2 is a novel prognostic factor in human esophageal squamous cell carcinoma",
abstract = "Background: FOXC2 has been implicated in cancer progression through its induction of epithelial-to-mesenchymal transition. We analyzed the clinical significance of FOXC2 in esophageal cancer cases, in which early distant metastasis or invasion to nearby organs is an obstacle to treatment. Methods: Quantitative reverse transcriptase-polymerase chain reaction was used to evaluate FOXC2 mRNA expression in 70 esophageal cancer cases to determine the clinicopathologic significance of FOXC2 expression. Furthermore, we examined associations between FOXC2 expression and matrix metalloproteinases 2 (MMP2) and matrix metalloproteinases 9 (MMP9). We also performed in vitro invasion and migration assays for FOXC2-suppressed esophageal cancer cells. Results: In clinicopathologic analysis, the high-FOXC2 expression group showed a higher incidence of advanced tumor stage, lymph node metastasis, and lymphatic invasion than the low-FOXC2 expression group (P < 0.05). In particular, tumor stage exhibited the most remarkable difference (P < 0.0001). Expression of MMP2 and MMP9 was far higher in the high-FOXC2 expression group. Furthermore, the high-FOXC2 expression group had a significantly poorer prognosis than did the low expression group (P = 0.006). Multivariate analysis indicated that high FOXC2 expression was an independent prognostic factor for survival. Suppression of FOXC2 expression altered the invasive and the migratory ability of esophageal cancer cells in vitro. Conclusions: Our findings suggest that FOXC2 could be an important prognostic indicator for esophageal cancer patients. FOXC2 is directly involved in cancer progression and is associated with poor prognosis in esophageal cancer cases.",
author = "Naohiro Nishida and Koshi Mimori and Takehiko Yokobori and Tomoya Sudo and Fumiaki Tanaka and Kohei Shibata and Hideshi Ishii and Yuichiro Doki and Masaki Mori",
year = "2011",
month = "2",
day = "1",
doi = "10.1245/s10434-010-1274-y",
language = "English",
volume = "18",
pages = "535--542",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - FOXC2 is a novel prognostic factor in human esophageal squamous cell carcinoma

AU - Nishida, Naohiro

AU - Mimori, Koshi

AU - Yokobori, Takehiko

AU - Sudo, Tomoya

AU - Tanaka, Fumiaki

AU - Shibata, Kohei

AU - Ishii, Hideshi

AU - Doki, Yuichiro

AU - Mori, Masaki

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Background: FOXC2 has been implicated in cancer progression through its induction of epithelial-to-mesenchymal transition. We analyzed the clinical significance of FOXC2 in esophageal cancer cases, in which early distant metastasis or invasion to nearby organs is an obstacle to treatment. Methods: Quantitative reverse transcriptase-polymerase chain reaction was used to evaluate FOXC2 mRNA expression in 70 esophageal cancer cases to determine the clinicopathologic significance of FOXC2 expression. Furthermore, we examined associations between FOXC2 expression and matrix metalloproteinases 2 (MMP2) and matrix metalloproteinases 9 (MMP9). We also performed in vitro invasion and migration assays for FOXC2-suppressed esophageal cancer cells. Results: In clinicopathologic analysis, the high-FOXC2 expression group showed a higher incidence of advanced tumor stage, lymph node metastasis, and lymphatic invasion than the low-FOXC2 expression group (P < 0.05). In particular, tumor stage exhibited the most remarkable difference (P < 0.0001). Expression of MMP2 and MMP9 was far higher in the high-FOXC2 expression group. Furthermore, the high-FOXC2 expression group had a significantly poorer prognosis than did the low expression group (P = 0.006). Multivariate analysis indicated that high FOXC2 expression was an independent prognostic factor for survival. Suppression of FOXC2 expression altered the invasive and the migratory ability of esophageal cancer cells in vitro. Conclusions: Our findings suggest that FOXC2 could be an important prognostic indicator for esophageal cancer patients. FOXC2 is directly involved in cancer progression and is associated with poor prognosis in esophageal cancer cases.

AB - Background: FOXC2 has been implicated in cancer progression through its induction of epithelial-to-mesenchymal transition. We analyzed the clinical significance of FOXC2 in esophageal cancer cases, in which early distant metastasis or invasion to nearby organs is an obstacle to treatment. Methods: Quantitative reverse transcriptase-polymerase chain reaction was used to evaluate FOXC2 mRNA expression in 70 esophageal cancer cases to determine the clinicopathologic significance of FOXC2 expression. Furthermore, we examined associations between FOXC2 expression and matrix metalloproteinases 2 (MMP2) and matrix metalloproteinases 9 (MMP9). We also performed in vitro invasion and migration assays for FOXC2-suppressed esophageal cancer cells. Results: In clinicopathologic analysis, the high-FOXC2 expression group showed a higher incidence of advanced tumor stage, lymph node metastasis, and lymphatic invasion than the low-FOXC2 expression group (P < 0.05). In particular, tumor stage exhibited the most remarkable difference (P < 0.0001). Expression of MMP2 and MMP9 was far higher in the high-FOXC2 expression group. Furthermore, the high-FOXC2 expression group had a significantly poorer prognosis than did the low expression group (P = 0.006). Multivariate analysis indicated that high FOXC2 expression was an independent prognostic factor for survival. Suppression of FOXC2 expression altered the invasive and the migratory ability of esophageal cancer cells in vitro. Conclusions: Our findings suggest that FOXC2 could be an important prognostic indicator for esophageal cancer patients. FOXC2 is directly involved in cancer progression and is associated with poor prognosis in esophageal cancer cases.

UR - http://www.scopus.com/inward/record.url?scp=79951551966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951551966&partnerID=8YFLogxK

U2 - 10.1245/s10434-010-1274-y

DO - 10.1245/s10434-010-1274-y

M3 - Article

C2 - 20803080

AN - SCOPUS:79951551966

VL - 18

SP - 535

EP - 542

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 2

ER -